{"id":"https://openalex.org/W3013512820","doi":"https://doi.org/10.1016/j.ophtha.2020.03.020","title":"Long-term Visual Outcomes after Release from Protocol in Patients who Participated in the Inhibition of VEGF in Age-related Choroidal Neovascularisation (IVAN) Trial","display_name":"Long-term Visual Outcomes after Release from Protocol in Patients who Participated in the Inhibition of VEGF in Age-related Choroidal Neovascularisation (IVAN) Trial","publication_year":2020,"publication_date":"2020-03-27","ids":{"openalex":"https://openalex.org/W3013512820","doi":"https://doi.org/10.1016/j.ophtha.2020.03.020","mag":"3013512820","pmid":"https://pubmed.ncbi.nlm.nih.gov/32359843","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/7471837"},"language":"en","primary_location":{"id":"doi:10.1016/j.ophtha.2020.03.020","doi":"https://doi.org/10.1016/j.ophtha.2020.03.020","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.ophtha.2020.03.020","pdf_url":"http://www.aaojournal.org/article/S0161642020303031/pdf","source":{"id":"https://openalex.org/S207341048","display_name":"Ophthalmology","issn_l":"0161-6420","issn":["0161-6420","1549-4713"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Ophthalmology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"http://www.aaojournal.org/article/S0161642020303031/pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5054954472","display_name":"Rebecca Evans","orcid":"https://orcid.org/0000-0002-7119-8187","observed_orcids":["https://orcid.org/0000-0002-7119-8187"]},"institutions":[{"id":"https://openalex.org/I36234482","display_name":"University of Bristol","ror":"https://ror.org/0524sp257","country_code":"GB","type":"education","lineage":["https://openalex.org/I36234482"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Rebecca N. Evans","raw_affiliation_strings":["Clinical Trials and Evaluation Unit, Bristol Trials Centre, Bristol Medical School, University of Bristol, Bristol, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Trials and Evaluation Unit, Bristol Trials Centre, Bristol Medical School, University of Bristol, Bristol, United Kingdom","institution_ids":["https://openalex.org/I36234482"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049611346","display_name":"Barnaby C Reeves","orcid":"https://orcid.org/0000-0002-5101-9487","observed_orcids":["https://orcid.org/0000-0002-5101-9487"]},"institutions":[{"id":"https://openalex.org/I36234482","display_name":"University of Bristol","ror":"https://ror.org/0524sp257","country_code":"GB","type":"education","lineage":["https://openalex.org/I36234482"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Barnaby C. Reeves","raw_affiliation_strings":["Clinical Trials and Evaluation Unit, Bristol Trials Centre, Bristol Medical School, University of Bristol, Bristol, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Trials and Evaluation Unit, Bristol Trials Centre, Bristol Medical School, University of Bristol, Bristol, United Kingdom","institution_ids":["https://openalex.org/I36234482"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Dawn Phillips","orcid":"https://orcid.org/0000-0002-1322-472X","observed_orcids":["https://orcid.org/0000-0002-1322-472X"]},"institutions":[{"id":"https://openalex.org/I36234482","display_name":"University of Bristol","ror":"https://ror.org/0524sp257","country_code":"GB","type":"education","lineage":["https://openalex.org/I36234482"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Dawn Phillips","raw_affiliation_strings":["Clinical Trials and Evaluation Unit, Bristol Trials Centre, Bristol Medical School, University of Bristol, Bristol, United Kingdom"],"raw_orcid":"https://orcid.org/0000-0002-1322-472X","affiliations":[{"raw_affiliation_string":"Clinical Trials and Evaluation Unit, Bristol Trials Centre, Bristol Medical School, University of Bristol, Bristol, United Kingdom","institution_ids":["https://openalex.org/I36234482"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109376795","display_name":"Katherine Alyson Muldrew","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I126231945","display_name":"Queen's University Belfast","ror":"https://ror.org/00hswnk62","country_code":"GB","type":"education","lineage":["https://openalex.org/I126231945"]},{"id":"https://openalex.org/I4210130048","display_name":"Royal Victoria Hospital","ror":"https://ror.org/03rq50d77","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1289110261","https://openalex.org/I4210130048"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Katherine Alyson Muldrew","raw_affiliation_strings":["Queen's University of Belfast, Royal Victoria Hospital, Belfast, Ireland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Queen's University of Belfast, Royal Victoria Hospital, Belfast, Ireland","institution_ids":["https://openalex.org/I126231945","https://openalex.org/I4210130048"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5007945636","display_name":"Chris A. Rogers","orcid":"https://orcid.org/0000-0002-9624-2615","observed_orcids":["https://orcid.org/0000-0002-9624-2615"]},"institutions":[{"id":"https://openalex.org/I36234482","display_name":"University of Bristol","ror":"https://ror.org/0524sp257","country_code":"GB","type":"education","lineage":["https://openalex.org/I36234482"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Chris Rogers","raw_affiliation_strings":["Clinical Trials and Evaluation Unit, Bristol Trials Centre, Bristol Medical School, University of Bristol, Bristol, United Kingdom"],"raw_orcid":"https://orcid.org/0000-0002-9624-2615","affiliations":[{"raw_affiliation_string":"Clinical Trials and Evaluation Unit, Bristol Trials Centre, Bristol Medical School, University of Bristol, Bristol, United Kingdom","institution_ids":["https://openalex.org/I36234482"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072357388","display_name":"Simon Peter Harding","orcid":"https://orcid.org/0000-0003-4676-1158","observed_orcids":["https://orcid.org/0000-0003-4676-1158"]},"institutions":[{"id":"https://openalex.org/I146655781","display_name":"University of Liverpool","ror":"https://ror.org/04xs57h96","country_code":"GB","type":"education","lineage":["https://openalex.org/I146655781"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Simon P. Harding","raw_affiliation_strings":["Department of Eye and Vision Science, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Eye and Vision Science, Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool, United Kingdom","institution_ids":["https://openalex.org/I146655781"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5019521414","display_name":"Usha Chakravarthy","orcid":"https://orcid.org/0000-0002-2606-3734","observed_orcids":["https://orcid.org/0000-0002-2606-3734"]},"institutions":[{"id":"https://openalex.org/I126231945","display_name":"Queen's University Belfast","ror":"https://ror.org/00hswnk62","country_code":"GB","type":"education","lineage":["https://openalex.org/I126231945"]},{"id":"https://openalex.org/I4210130048","display_name":"Royal Victoria Hospital","ror":"https://ror.org/03rq50d77","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1289110261","https://openalex.org/I4210130048"]}],"countries":["GB"],"is_corresponding":true,"raw_author_name":"Usha Chakravarthy","raw_affiliation_strings":["Queen's University of Belfast, Royal Victoria Hospital, Belfast, Ireland. Electronic address: u.chakravarthy@qub.ac.uk","Queen's University of Belfast, Royal Victoria Hospital, Belfast, Ireland"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Queen's University of Belfast, Royal Victoria Hospital, Belfast, Ireland. Electronic address: u.chakravarthy@qub.ac.uk","institution_ids":["https://openalex.org/I126231945","https://openalex.org/I4210130048"]},{"raw_affiliation_string":"Queen's University of Belfast, Royal Victoria Hospital, Belfast, Ireland","institution_ids":["https://openalex.org/I126231945","https://openalex.org/I4210130048"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5019521414"],"corresponding_institution_ids":["https://openalex.org/I126231945","https://openalex.org/I4210130048"],"apc_list":{"value":3300,"currency":"USD","value_usd":3300},"apc_paid":{"value":3300,"currency":"USD","value_usd":3300},"fwci":3.7708,"has_fulltext":true,"cited_by_count":28,"citation_normalized_percentile":{"value":0.9421192,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":99},"biblio":{"volume":"127","issue":"9","first_page":"1191","last_page":"1200"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10170","display_name":"Retinal Diseases and Treatments","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10170","display_name":"Retinal Diseases and Treatments","score":0.9970999956130981,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11194","display_name":"Ocular Diseases and Beh\u00e7et\u2019s Syndrome","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2731","display_name":"Ophthalmology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11377","display_name":"Retinal and Macular Surgery","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/neovascular-age-related-macular-degeneration","display_name":"neovascular age-related macular degeneration","score":0.9769999980926514},{"id":"https://openalex.org/keywords/choroidal-neovascularization","display_name":"choroidal neovascularization","score":0.8650000095367432},{"id":"https://openalex.org/keywords/anti-vegf-therapy","display_name":"anti-VEGF therapy","score":0.847000002861023},{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":0.8650000095367432},{"id":"https://openalex.org/keywords/ranibizumab","display_name":"ranibizumab","score":1.0},{"id":"https://openalex.org/keywords/aflibercept","display_name":"aflibercept","score":0.9959999918937683},{"id":"https://openalex.org/keywords/visual-acuity-outcomes","display_name":"visual acuity outcomes","score":0.578000009059906},{"id":"https://openalex.org/keywords/long-term-visual-outcomes","display_name":"long-term visual outcomes","score":0.6060000061988831},{"id":"https://openalex.org/keywords/treatment-frequency","display_name":"treatment frequency","score":0.3720000088214874},{"id":"https://openalex.org/keywords/follow-up-completeness","display_name":"follow-up completeness","score":0.32899999618530273}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9575284123420715},{"id":"https://openalex.org/C119060515","wikidata":"https://www.wikidata.org/wiki/Q1916617","display_name":"Interquartile range","level":2,"score":0.8387681245803833},{"id":"https://openalex.org/C2781100027","wikidata":"https://www.wikidata.org/wiki/Q414270","display_name":"Ranibizumab","level":4,"score":0.8263969421386719},{"id":"https://openalex.org/C2776403814","wikidata":"https://www.wikidata.org/wiki/Q27429789","display_name":"Macular degeneration","level":2,"score":0.7587140798568726},{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.6309967041015625},{"id":"https://openalex.org/C2778257484","wikidata":"https://www.wikidata.org/wiki/Q555066","display_name":"Visual acuity","level":2,"score":0.6163066029548645},{"id":"https://openalex.org/C118487528","wikidata":"https://www.wikidata.org/wiki/Q161437","display_name":"Ophthalmology","level":1,"score":0.5794387459754944},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.5598043203353882},{"id":"https://openalex.org/C72563966","wikidata":"https://www.wikidata.org/wiki/Q1303415","display_name":"Cohort","level":2,"score":0.5421115159988403},{"id":"https://openalex.org/C2781359195","wikidata":"https://www.wikidata.org/wiki/Q5105209","display_name":"Choroidal neovascularization","level":3,"score":0.45931628346443176},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.3386988639831543},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3116150498390198},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.0970030128955841}],"mesh":[{"descriptor_ui":"D000068258","descriptor_name":"Bevacizumab","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000069579","descriptor_name":"Ranibizumab","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005500","descriptor_name":"Follow-Up Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010358","descriptor_name":"Patient Participation","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011795","descriptor_name":"Surveys and Questionnaires","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014792","descriptor_name":"Visual Acuity","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018434","descriptor_name":"Sickness Impact Profile","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D020256","descriptor_name":"Choroidal Neovascularization","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D020256","descriptor_name":"Choroidal Neovascularization","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":false},{"descriptor_ui":"D020533","descriptor_name":"Angiogenesis Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D042461","descriptor_name":"Vascular Endothelial Growth Factor A","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D057135","descriptor_name":"Wet Macular Degeneration","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D057135","descriptor_name":"Wet Macular Degeneration","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":false},{"descriptor_ui":"D058449","descriptor_name":"Intravitreal Injections","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":6,"locations":[{"id":"doi:10.1016/j.ophtha.2020.03.020","doi":"https://doi.org/10.1016/j.ophtha.2020.03.020","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.ophtha.2020.03.020","pdf_url":"http://www.aaojournal.org/article/S0161642020303031/pdf","source":{"id":"https://openalex.org/S207341048","display_name":"Ophthalmology","issn_l":"0161-6420","issn":["0161-6420","1549-4713"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Ophthalmology","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:7471837","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/7471837","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Ophthalmology","raw_type":"Text"},{"id":"pmid:32359843","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/32359843","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Ophthalmology","raw_type":"Journal Article"},{"id":"pmh:oai:research-information.bris.ac.uk:openaire_cris_publications/5fff1386-0b7b-4b94-8477-6bbea1f9721c","doi":null,"is_oa":true,"landing_page_url":"https://research-information.bris.ac.uk/en/publications/5fff1386-0b7b-4b94-8477-6bbea1f9721c","pdf_url":null,"source":{"id":"https://openalex.org/S4306400895","display_name":"Bristol Research (University of Bristol)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I36234482","host_organization_name":"University of Bristol","host_organization_lineage":["https://openalex.org/I36234482"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Evans, R N, Reeves, B C, Phillips, D, Harding, S, Muldrew, A, Rogers, C A & Chakravarthy, U 2020, 'Long-term Visual Outcomes after Release from Protocol in Patients who Participated in the Inhibition of VEGF in Age-related choroidal Neovascularisation (IVAN) Trial', Ophthalmology, vol. 127, no. 9, pp. 1191-1200. https://doi.org/10.1016/j.ophtha.2020.03.020","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:oai:research-information.bris.ac.uk:openaire/5fff1386-0b7b-4b94-8477-6bbea1f9721c","doi":null,"is_oa":true,"landing_page_url":"https://research-information.bris.ac.uk/en/publications/5fff1386-0b7b-4b94-8477-6bbea1f9721c","pdf_url":"https://research-information.bris.ac.uk/files/254485688/PIIS0161642020303031.pdf","source":{"id":"https://openalex.org/S7407055359","display_name":"Explore Bristol Research","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Evans, R N, Reeves, B C, Phillips, D, Harding, S, Muldrew, A, Rogers, C A & Chakravarthy, U 2020, 'Long-term Visual Outcomes after Release from Protocol in Patients who Participated in the Inhibition of VEGF in Age-related choroidal Neovascularisation (IVAN) Trial', Ophthalmology, vol. 127, no. 9, pp. 1191-1200. https://doi.org/10.1016/j.ophtha.2020.03.020","raw_type":"info:eu-repo/semantics/article"},{"id":"pmh:oai:pure.qub.ac.uk/portal:openaire/00695c30-881e-45c0-b3ac-ba3bc9969f26","doi":null,"is_oa":true,"landing_page_url":"https://pure.qub.ac.uk/en/publications/00695c30-881e-45c0-b3ac-ba3bc9969f26","pdf_url":null,"source":{"id":"https://openalex.org/S4306402319","display_name":"Research Portal (Queen's University Belfast)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I126231945","host_organization_name":"Queen's University Belfast","host_organization_lineage":["https://openalex.org/I126231945"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"IVAN Study Group 2020, 'Long-term Visual Outcomes after Release from Protocol in Patients who Participated in the Inhibition of VEGF in Age-related choroidal Neovascularisation (IVAN) Trial', Ophthalmology, vol. 127, no. 9, pp. 1191. https://doi.org/10.1016/j.ophtha.2020.03.020","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":{"id":"doi:10.1016/j.ophtha.2020.03.020","doi":"https://doi.org/10.1016/j.ophtha.2020.03.020","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.ophtha.2020.03.020","pdf_url":"http://www.aaojournal.org/article/S0161642020303031/pdf","source":{"id":"https://openalex.org/S207341048","display_name":"Ophthalmology","issn_l":"0161-6420","issn":["0161-6420","1549-4713"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Ophthalmology","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9940000176429749,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G1970737554","display_name":"A randomised controlled trial (RCT) of alternative treatments to Inhibit VEGF in patients with Age-related choroidal Neovascularisation (IVAN)","funder_award_id":"07/36/01","funder_id":"https://openalex.org/F4320319990","funder_display_name":"National Institute for Health and Care Research"}],"funders":[{"id":"https://openalex.org/F4320319990","display_name":"National Institute for Health and Care Research","ror":"https://ror.org/0187kwz08"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W3013512820.pdf","grobid_xml":"https://content.openalex.org/works/W3013512820.grobid-xml"},"referenced_works_count":17,"referenced_works":["https://openalex.org/W633153563","https://openalex.org/W1938936218","https://openalex.org/W2079370245","https://openalex.org/W2083043469","https://openalex.org/W2095329410","https://openalex.org/W2154073405","https://openalex.org/W2343042175","https://openalex.org/W2418354957","https://openalex.org/W2473786944","https://openalex.org/W2520946895","https://openalex.org/W2738996050","https://openalex.org/W2747836769","https://openalex.org/W2754502683","https://openalex.org/W2786342493","https://openalex.org/W2789226077","https://openalex.org/W2887429619","https://openalex.org/W2905226282"],"related_works":["https://openalex.org/W3057057562","https://openalex.org/W633153563","https://openalex.org/W2011751119","https://openalex.org/W2154073405","https://openalex.org/W6892362726","https://openalex.org/W2991567589","https://openalex.org/W3195747806","https://openalex.org/W2801761853","https://openalex.org/W2754502683","https://openalex.org/W2036910617"],"abstract_inverted_index":{"PURPOSE:":[0],"To":[1],"describe":[2],"visual":[3,101,344],"outcomes,":[4],"frequency":[5,174],"of":[6,59,127,133,137,145,147,152,191,197,240,259,269,289,304,312],"treatment":[7,29,173,336],"and":[8,11,73,96,109,172,175,211,335],"monitoring":[9,200],"visits,":[10],"anti-vascular":[12,178],"endothelial":[13,179],"growth":[14,180],"factor":[15,181],"drugs":[16],"used":[17],"in":[18,21,27,56,61,84,106,177,242,315,342],"usual":[19,119],"care":[20,120],"participants":[22,69,129,253,279],"who":[23,74,280],"exited":[24],"a":[25,161,308],"trial":[26,51,330],"which":[28],"for":[30,111,188,246,306,328],"neovascular":[31],"age-related":[32],"macular":[33],"degeneration":[34],"(nAMD)":[35],"was":[36,204,214,276,319],"initiated":[37],"with":[38,265,301],"bevacizumab":[39],"or":[40,76,282],"ranibizumab.":[41],"DESIGN:":[42],"Multicenter":[43],"cohort":[44],"study":[45,138,154,198,290,299,317],"up":[46],"to":[47,114,272,321],"7":[48],"years":[49,206,295],"after":[50,67,201,244,296],"exit.":[52],"PARTICIPANTS:":[53],"Patients":[54],"enrolled":[55],"the":[57,79,131,153,238,287,297,310,316],"Inhibition":[58],"VEGF":[60],"Age-related":[62],"choroidal":[63],"Neovascularisation":[64],"(IVAN)":[65],"trial;":[66],"excluding":[68],"from":[70,124],"2":[71],"sites":[72],"died":[75],"withdrew":[77],"during":[78,149],"trial,":[80,309],"537":[81],"were":[82,90,122,170,186,262,338],"included":[83],"this":[85],"follow-up":[86,305],"cohort.":[87],"METHODS:":[88],"Data":[89,185],"collected":[91],"between":[92],"May":[93],"26,":[94],"2016,":[95],"August":[97],"24,":[98],"2017.":[99],"Distance":[100],"acuity":[102,345],"(DVA)":[103],"(letters":[104],"read)":[105],"both":[107],"eyes":[108],"treatments":[110],"nAMD":[112],"administered":[113],"either":[115],"eye":[116,139,155,157,199,220,318],"at":[117,286],"all":[118,128],"visits":[121],"extracted":[123],"medical":[125],"records":[126],"until":[130],"point":[132],"data":[134],"collection":[135],"(duration":[136],"monitoring).":[140],"MAIN":[141],"OUTCOME":[142],"MEASURES:":[143],"Rate":[144],"change":[146,241],"DVA":[148,213,221,243,275],"active":[150],"surveillance":[151],"(study":[156],"monitoring),":[158],"estimated":[159],"using":[160],"multivariable":[162],"linear":[163],"random":[164],"effects":[165],"model.":[166],"Other":[167],"outcome":[168],"measures":[169],"visit":[171],"switches":[176,337],"(VEGF)":[182],"drug.":[183],"RESULTS:":[184],"obtained":[187],"99%":[189],"(532/537)":[190],"eligible":[192],"participants.":[193],"The":[194,274],"median":[195,212],"duration":[196],"IVAN":[202,250,298],"exit":[203],"3.3":[205],"(interquartile":[207],"range":[208],"[IQR],":[209],"1.3-4.7),":[210],"58.0":[215],"letters":[216,230],"(IQR,":[217],"34.0-73.0).":[218],"Study":[219],"deteriorated":[222],"by":[223],"4.3":[224],"(95%":[225],"confidence":[226],"interval":[227],"[CI],":[228],"3.7-4.9)":[229],"per":[231],"year.":[232],"Injection":[233],"rate":[234,239],"did":[235,283],"not":[236,284,339],"influence":[237],"adjusting":[245],"key":[247],"covariates.":[248],"After":[249],"exit,":[251],"174":[252],"(32%)":[254],"received":[255],"no":[256],"treatment;":[257],"332":[258],"358":[260],"(93%)":[261],"treated":[263],"first":[264],"ranibizumab,":[266],"78":[267],"(23%)":[268],"whom":[270],"switched":[271,281],"aflibercept.":[273],"similar":[277],"among":[278],"switch":[285],"end":[288],"monitoring.":[291],"CONCLUSIONS:":[292],"Approximately":[293],"5":[294],"finished,":[300],"unprecedented":[302],"completeness":[303],"such":[307],"trajectory":[311],"functional":[313],"decline":[314],"shown":[320],"be":[322],"greater":[323],"than":[324],"that":[325],"previously":[326],"reported":[327],"incomplete":[329],"cohorts.":[331],"Anti-VEGF":[332],"injection":[333],"rates":[334],"important":[340],"factors":[341],"determining":[343],"outcomes.":[346]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":4},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":7},{"year":2022,"cited_by_count":6},{"year":2021,"cited_by_count":5},{"year":2020,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2020-04-03T00:00:00"}